Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
James R. Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), recently executed a series of transactions involving the company’s common shares. According to a Form 4 filing with the Securities and Exchange Commission, Kasinger sold a total of 11,542 shares over two days, resulting in a total transaction value of $619,492. The shares were sold at prices ranging from $52.8 to $53.85. The stock, currently trading at $53.02, has shown significant momentum with a 20.6% gain in the past week, according to InvestingPro data.
The sales were conducted to cover tax obligations related to the vesting of restricted stock units, as mandated by the company’s RSU Settlement Policy. Following these transactions, Kasinger holds 74,880 shares directly. InvestingPro analysis shows CRISPR maintains strong financial health with a current ratio of 22.07, indicating robust liquidity.
In addition to the sales, Kasinger also acquired a total of 23,825 common shares through the exercise of restricted stock units on February 16 and February 18. These transactions did not involve any cash consideration, as each restricted stock unit represents a contingent right to receive one share of CRISPR common stock.
These transactions reflect a mix of routine stock option exercises and mandated sales to cover tax liabilities, rather than discretionary trades by the executive.
In other recent news, CRISPR Therapeutics has been the focus of several analyst updates and developments. The company recently reported growth in Casgevy cell collections, with over 50 new collections in the final weeks of the fourth quarter, indicating continued expansion. Citi analysts adjusted their price target for CRISPR Therapeutics to $82, maintaining a Buy rating, and highlighted the company’s expanding pipeline with significant developments expected in 2025. Evercore ISI upgraded the stock to an Outperform rating, raising the price target to $99, driven by optimism about upcoming catalysts and the company’s strong cash position of $1.9 billion. Meanwhile, Stifel adjusted its price target to $49, maintaining a Hold rating, reflecting a cautious outlook on Casgevy’s market uptake but acknowledging potential in the pipeline. TD Cowen also upgraded the stock from Sell to Hold, keeping the price target at $35, citing reduced downside risk. These recent analyses underscore the varied perspectives on CRISPR Therapeutics’ potential, with a focus on both the current market performance of Casgevy and the anticipated progress of the company’s broader pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.